Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19.

Bozkurt, Biykem; Kovacs, Richard; Harrington, Bob

Bozkurt, Biykem; Kovacs, Richard; Harrington, Bob.

J Card Fail ; 26(5): 370, 2020 05.

Article in English | MEDLINE | ID: covidwho-325155

Subject(s)

Angiotensin Receptor Antagonists/pharmacology; Angiotensin-Converting Enzyme Inhibitors/pharmacology; Betacoronavirus; Coronavirus Infections; Heart Failure; Pandemics; Pneumonia, Viral; American Heart Association; Betacoronavirus/drug effects; Betacoronavirus/physiology; COVID-19; Comorbidity; Consensus; Coronavirus Infections/epidemiology; Coronavirus Infections/therapy; Heart Failure/drug therapy; Heart Failure/epidemiology; Humans; Pneumonia, Viral/epidemiology; Pneumonia, Viral/therapy; Renin-Angiotensin System/drug effects; Renin-Angiotensin System/physiology; Risk Assessment; SARS-CoV-2; Standard of Care; United States

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Angiotensin-Converting Enzyme Inhibitors / Coronavirus Infections / Angiotensin Receptor Antagonists / Pandemics / Betacoronavirus / Heart Failure Type of study: Observational study / Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: J Card Fail Journal subject: Cardiology Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google